Revelation Biosciences (REVB) Operating Expenses (2020 - 2026)
Revelation Biosciences (REVB) posted quarterly Operating Expenses of $2.6 million for Q4 2025, up 46.62% year-over-year from $1.8 million in Q4 2024, and up 32.35% quarter-over-quarter from $1.9 million in Q3 2025.
Revelation Biosciences (REVB) Operating Expenses (2020 - 2026) Analysis & Trends
Revelation Biosciences (REVB) has reported Operating Expenses for 6 consecutive years, with $2.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Operating Expenses rose 46.62% year-over-year to $2.6 million; the TTM figure through Dec 2025 stood at $9.1 million (up 13.74% YoY), while the FY2025 annual figure was $9.1 million, up 13.74% from the prior year.
- Operating Expenses improved to $2.6 million in Q4 2025 per REVB's latest filing, from $1.9 million in the prior quarter.
- Across five years, Operating Expenses topped out at $6.6 million in Q1 2022 and bottomed at $1.2 million in Q3 2022.
- Historically, Operating Expenses has averaged $2.4 million across 5 years, with a median of $2.2 million in 2023.
- Annual changes were most pronounced in 2021 — Operating Expenses jumped 350585.14% — and 2023, when it slumped 75.41%.
- Revelation Biosciences' Operating Expenses stood at $3.9 million in 2021, then tumbled by 68.41% to $1.2 million in 2022, then soared by 90.91% to $2.3 million in 2023, then fell by 24.59% to $1.8 million in 2024, then jumped by 46.62% to $2.6 million in 2025.
- Business Quant data shows REVB's Operating Expenses at $2.6 million in Q4 2025, $1.9 million in Q3 2025, and $2.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.65 Bn | 131.79 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.08 Bn | 78.09 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.16 Bn | 59.98 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 63.25 Bn | 58.11 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.26 Bn | 27.95 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.96 Bn | 10.57 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.19 Bn | 26.35 Bn | - | 541.02 Mn |
| 10 | Revelation Biosciences | 4.08 Mn | -7.42 Mn | - | 3.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.66 Mn |
| Dec 31, 2025 | 2.57 Mn |
| Sep 30, 2025 | 1.94 Mn |
| Jun 30, 2025 | 2.46 Mn |
| Mar 31, 2025 | 2.09 Mn |
| Dec 31, 2024 | 1.75 Mn |
| Sep 30, 2024 | 1.80 Mn |
| Jun 30, 2024 | 2.52 Mn |
| Mar 31, 2024 | 1.90 Mn |
| Dec 31, 2023 | 2.33 Mn |
| Sep 30, 2023 | 2.78 Mn |
| Jun 30, 2023 | 1.93 Mn |
| Mar 31, 2023 | 1.62 Mn |
| Dec 31, 2022 | 1.22 Mn |
| Sep 30, 2022 | 1.20 Mn |
| Jun 30, 2022 | 1.86 Mn |
| Mar 31, 2022 | 6.59 Mn |
| Dec 31, 2021 | 3.86 Mn |
| Sep 30, 2021 | 3.04 Mn |
| Jun 30, 2021 | 2.44 Mn |